Try our beta test site

Photodynamic Therapy in Treating Patients With Basal Cell Skin Cancer

This study has been completed.
National Cancer Institute (NCI)
Information provided by:
Roswell Park Cancer Institute Identifier:
First received: June 6, 2001
Last updated: March 3, 2011
Last verified: March 2011

RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill tumor cells. Photosensitizing drugs such as HPPH are absorbed by cancer cells and, when exposed to light, become active and kill the cancer cells.

PURPOSE: Phase I trial to study the effectiveness of photodynamic therapy with HPPH in treating patients who have basal cell skin cancer.

Condition Intervention Phase
Non-melanomatous Skin Cancer
Drug: HPPH
Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I Study Of Photodynamic Therapy (PDT) For The Treatment Of Basal Cell Carcinoma (BCC): A Drug/Light Dose Finding Study Utilizing 2-(1-HEXYLOXYETHYL)-2-DEVINYL PYROPHEOPHORBIDE-A (HPPH-PHOTOCLOR)

Resource links provided by NLM:

Further study details as provided by Roswell Park Cancer Institute:

Enrollment: 6
Study Start Date: January 2000
Study Completion Date: January 2007
Primary Completion Date: December 2006 (Final data collection date for primary outcome measure)
Detailed Description:


  • Determine the safety of HPPH used in photodynamic therapy in patients with basal cell skin cancer.
  • Determine the drug dose, light dose, and treatment interval combinations that do not produce excessive toxicity to normal skin but effect tumor response in these patients treated with this regimen.
  • Determine the length of time for cutaneous photosensitivity in these patients treated with this regimen.
  • Determine the plasma clearance rates for HPPH in these patients.
  • Determine the best combination of treatment parameters for a phase II study.

OUTLINE: This is a dose-escalation study.

Patients receive HPPH IV on day 1. Patients undergo phototherapy on days 2-3.

Cohorts of 2-6 patients receive escalating doses of HPPH and phototherapy to determine the minimum erythemal dose (MED). The MED is defined as the dose combination of HPPH and laser light preceding that at which at least 1 patient experiences grade 3 or worse toxicity or at which at least 2 patients experience grade 1 or worse toxicity.

Patients are followed daily for 4 days, at week 1, and at months 1, 3, 6, 12, and 24.

PROJECTED ACCRUAL: A total of 4-25 patients will be accrued for this study.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically confirmed non-morpheaform basal cell skin cancer

    • Primary disease OR
    • Recurrent disease after prior therapy (e.g., surgical excision, electrodesiccation, cryosurgery, or radiotherapy)
  • At least 4 lesions, no greater than 2 cm in diameter and no greater than 5 mm in depth
  • No lesions located on the eyelid, nose, ear, periauricular area, genitals, or digits, or any other lesions thought to be deep and/or aggressive



  • Over 18

Performance status:

  • Not specified

Life expectancy:

  • Not specified


  • WBC at least 2,000/mm^3
  • Platelet count at least 120,000/mm^3


  • PT/PTT no greater than 1.5 times upper limit of normal (ULN)
  • Bilirubin no greater than 3.0 mg/dL
  • Liver enzymes no greater than 2 times ULN
  • No impaired hepatic function


  • No impaired renal function


  • No myocardial infarction within the past 6 months


  • No porphyria
  • No known hypersensitivity to porphyrins
  • No systemic lupus erythematosus
  • No history of positive antinuclear antibody
  • No history of degenerative disease of the retina
  • No xeroderma pigmentosum
  • No pancreatic disease
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception


Biologic therapy:

  • Not specified


  • At least 3 months since prior combination doxorubicin and radiotherapy

Endocrine therapy:

  • Not specified


  • See Disease Characteristics
  • See Chemotherapy


  • See Disease Characteristics
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00017485

United States, New York
Roswell Park Cancer Institute
Buffalo, New York, United States, 14263-0001
Sponsors and Collaborators
Roswell Park Cancer Institute
National Cancer Institute (NCI)
Study Chair: Allan R. Oseroff, MD, PhD Roswell Park Cancer Institute
  More Information

Responsible Party: Alan Oseroff, MD, Roswell Park Cancer Institute Identifier: NCT00017485     History of Changes
Other Study ID Numbers: CDR0000068696
P30CA016056 ( US NIH Grant/Contract Award Number )
Study First Received: June 6, 2001
Last Updated: March 3, 2011

Keywords provided by Roswell Park Cancer Institute:
basal cell carcinoma of the skin
recurrent skin cancer

Additional relevant MeSH terms:
Carcinoma, Basal Cell
Skin Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms, Basal Cell
Neoplasms by Site
Skin Diseases processed this record on March 27, 2017